Lumicell
Newton, US · Founded 2009 · Delaware corporation · 63 employees on LinkedIn · 3 known investors
Find your way into Lumicell
3,613 people in our graph share verified history with the Lumicell team — schools, employers, funds. One of them is your warm intro.
Tianen Liangunlockedknows Julio Rodriguez · together at PwC (overlapped)
×6knows the team · via Massachusetts Institute of Technology
×3knows the team · via Stanford University
knows the team · via Harvard Business School
knows the team · via PwC
Lumicell develops a fluorescence-guided intraoperative imaging technology, including its LUMISIGHT optical imaging agent, that illuminates cancerous tissue in the surgical cavity to help surgeons remove residual cancer during procedures such as lumpectomy. The platform is aimed at surgical oncology, starting with breast cancer, and its flagship product has received FDA approval.
Founders & leadership
Lumicell was founded in 2009 by Jorge Ferrer and W. David Lee.
JF
Jorge FerrerinCo-founder · Chief Scientific OfficerJorge Ferrer holds a PhD in Bioengineering from MIT and serves as Co-Inventor and Chief Scientific Officer of Lumicell, where he has led clinical development, regulatory strategy, and translational research programs across oncology applications. He has secured substantial federal research funding from the National Cancer Institute and NSF SBIR programs to advance the company's fluorescence-guided surgical imaging platform.
WD
W. David LeeinMember Board of Directors, FounderDavid Lee is co-founder of Lumicell, developer of fluorescence-guided intraoperative imaging technology for surgical oncology. He has previously founded or co-founded Caveo Technology, T2 Biosystems, and Precision Healing, with experience spanning biotech, bioengineering, and product development.
HH
Howard HechlerinPresident & CEO2023–2025Howard Hechler is Executive Officer of Lumicell, which develops fluorescence-guided intraoperative imaging technology to help surgeons identify and remove cancerous tissue during surgical procedures. He brings medical device industry experience in corporate strategy, business development, and commercial planning.
MC
Marnie CurbowinChief Commercial Officer
JR
Julio RodriguezinHead of FinanceJulio Rodriguez is Head of Finance at Lumicell, where he leads financial operations for the company's FDA-approved fluorescence-guided surgical imaging platform. He brings 15+ years of healthcare and medtech finance experience from Big-4 and consulting roles, with expertise in FP&A, M&A due diligence, and scaling operations from clinical through commercial stages.
Board
CF
Cosimo FiorenzaBoard director
DF
David FurneauxBoard director
AZ
Andrey ZarurinCo-Founder & Chairman of the Board of DirectorsExecutive Officer, Director at GreenLight Biosciences
MR
Mike RuettgersBoard director
KK
Kevin KrenitskyBoard director
MB
Moungi BawendiBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$328.4M disclosed across 8 rounds · 2013–2025
▶$198.1MraisedMay 2025 · 64 investors · BiotechnologyRule 506(b)
▶$198.1MraisedMay 2025 · 64 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrey J. ZarurDirector
- Elon BomsDirector
- Jorge FerrerExecutive Officer
- David FurneauxDirector
- Kevin KrenitskyDirector
- James AlecxihDirector
- Carlos GonzalezDirector
- Howard HechlerExecutive Officer, Director
- Amount sold
- $198.1M
- Sales commissions
- $395.6K
- Placement agents
- Network 1 Financial Securities Inc.
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedJul 2024 · 11 investors · BiotechnologyRule 506(b)
▶$2.7MraisedJul 2024 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cosimo FiorenzaDirector
- Mike RuettgersDirector
- David FurneauxDirector
- Elon BomsDirector
- Andrey ZarurDirector
- Jorge FerrerExecutive Officer
- Howard HechlerExecutive Officer
- Kevin KrenitskyDirector
- W. David LeeDirector
- Offering amount
- $12M
- Amount sold
- $2.7M
- Sales commissions
- $2.5K
- Placement agents
- Network 1 Financial Securities Inc.
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedMar 2024 · 6 investors · BiotechnologyRule 506(b)
▶$2.3MraisedMar 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David FurneauxDirector
- W. David LeeDirector
- Elon BomsDirector
- Cosimo FiorenzaDirector
- Andrey ZarurDirector
- Mike RuettgersDirector
- Jorge FerrerExecutive Officer
- Howard HechlerExecutive Officer
- Kevin KrenitskyDirector
- Amount sold
- $2.3M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$75.8MraisedJul 2023 · 47 investors · BiotechnologyRule 506(b)
▶$75.8MraisedJul 2023 · 47 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- W. David LeeDirector
- Kevin KrenitskyDirector
- Michael RuettgersDirector
- David FurneauxDirector
- Kevin HershbergerExecutive Officer, Director
- Cosimo FiorenzaDirector
- Moungi BawendiDirector
- Andrey ZarurDirector
- Ralph WeisslederDirector
- Offering amount
- $110.2M
- Amount sold
- $75.8M
- Placement agents
- Network Financial Securities Inc.
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.4MraisedDec 2018 · 25 investors · BiotechnologyRule 506(b)
▶$20.4MraisedDec 2018 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin KrenitskyDirector
- Andrey ZarurExecutive Officer, Director
- Michael RuettgersDirector
- Kelly LondyExecutive Officer, Director
- Moungi BawendiDirector
- David FurneauxDirector
- W. David LeeExecutive Officer, Director
- Ralph WeisslederDirector
- Kevin HershbergerExecutive Officer
- Offering amount
- $35M
- Amount sold
- $20.4M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.7MraisedOct 2017 · 24 investors · BiotechnologyRule 506(b)
▶$20.7MraisedOct 2017 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- KEVIN KRENITSKYDirector
- W. DAVID LEEExecutive Officer, Director
- MOUNGI BAWENDIDirector
- ANDREY ZARURExecutive Officer, Director
- DAVID FURNEAUXDirector
- RALPH WEISSLEDERDirector
- JAMES SCHUERMANNDirector
- KELLY LONDYExecutive Officer, Director
- Offering amount
- $26.5M
- Amount sold
- $20.7M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.8MraisedMay 2016 · 10 investors · BiotechnologyRule 506(b)
▶$6.8MraisedMay 2016 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- ANDREY ZARURExecutive Officer, Director
- DAVID FURNEAUXDirector
- KEVIN KRENITSKYDirector
- W. DAVID LEEExecutive Officer, Director
- MOUNGI BAWENDIDirector
- RALPH WEISSLEDERDirector
- JAMES SCHUERMANNDirector
- Offering amount
- $10M
- Amount sold
- $6.8M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedFeb 2014 · 7 investors · BiotechnologyRule 506(b)
▶$1.6MraisedFeb 2014 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ralph WeisslederDirector
- Moungi BawendiDirector
- Andrey ZarurExecutive Officer, Director
- W. David LeeExecutive Officer, Director
- David FurneauxDirector
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapOmnicell Nasdomcl21 shared keywordsOmnicell develops medication management and automation solutions for healthcare facilities, enabling autonomous pharmacy operations across various care settings.
Lyell19 shared keywordsLyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology. The company operates an integrated pipeline spanning discovery through manufacturing and clinical trials, with its own manufacturing facility in Washington.
Globaldata11 shared keywordsGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
Companies competing with Lumicell for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $838.3K |
| National Science Foundation | Phase II | 2012 | $494.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $248.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $212.8K |
| National Science Foundation | Phase I | 2011 | $147.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Lumicell do?
- Lumicell develops a fluorescence-guided intraoperative imaging technology, including its LUMISIGHT optical imaging agent, that illuminates cancerous tissue in the surgical cavity to help surgeons remove residual cancer during procedures such as lumpectomy. The platform is aimed at surgical oncology, starting with breast cancer, and its flagship product has received FDA approval.
- Who founded Lumicell?
- Lumicell was founded by Jorge Ferrer, W. David Lee in 2009.
- Who are Lumicell's investors?
- Lumicell's investors include Kinled Holding, LaunchCapital, Launch Capital.
- How much funding has Lumicell raised?
- Lumicell has disclosed $328.4M raised across 8 rounds.
- Where is Lumicell headquartered?
- Lumicell is headquartered in Newton, US.